DIAPID
Clinical safety rating
cautionComprehensive clinical and safety monograph for DIAPID (DIAPID).
Comprehensive clinical and safety monograph for DIAPID (DIAPID).
Diabetes insipidus (central)Nocturnal enuresis (off-label)
Diapid (lypressin) is a synthetic analog of vasopressin that acts as an antidiuretic by increasing water reabsorption in the renal collecting ducts via V2 receptor activation. It also has mild vasopressor activity via V1 receptor stimulation.
| Metabolism | Lypressin is rapidly metabolized by peptidases in the liver and kidneys, with a half-life of approximately 15 minutes. |
| Excretion | Primarily renal excretion as unchanged drug (80-90%); minor biliary/fecal elimination (<10%) |
| Half-life | Terminal elimination half-life is 1.5-3 hours; clinically significant in patients with renal impairment, requiring dose adjustment |
| Protein binding | 20-30% bound to plasma proteins |
| Volume of Distribution | 0.6-0.8 L/kg; distributes primarily in extracellular fluid |
| Bioavailability | 100% by intravenous route; Not bioavailable orally |
| Onset of Action | Intravenous: 1-2 minutes; Oral: Not applicable (IV use only) |
| Duration of Action | Duration is 10-30 minutes after IV bolus; titratable by continuous infusion |
| Molecular Weight | 445.55 |
Intravenous bolus of 20 mg followed by 20-40 mg every 2-4 hours as needed. Maximum single dose: 80 mg.
| Dosage form | SOLUTION |
| Renal impairment | No adjustment required for GFR >30 mL/min. For GFR 10-30 mL/min: reduce dose by 50%. For GFR <10 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated. |
| Pediatric use | 0.2 mg/kg intravenously, repeat every 2 hours as needed. Maximum dose: 10 mg. |
| Geriatric use | Initial dose of 10 mg intravenously, titrate cautiously due to increased sensitivity. Maximum single dose: 40 mg. |
| 1st trimester | Diapide (glipizide) is contraindicated in the first trimester due to potential teratogenic effects. Insulin is preferred for glycemic control during organogenesis. |
| 2nd trimester | Use with caution in the second trimester; may be considered if insulin therapy is not feasible. Monitor for fetal hypoglycemia and macrosomia. |
| 3rd trimester | Use with caution; increased risk of neonatal hypoglycemia. Discontinue at least 2 days before elective delivery to prevent prolonged neonatal hypoglycemia. |
Clinical note
Comprehensive clinical and safety monograph for DIAPID (DIAPID).
| Placental transfer | Glipizide crosses the placenta moderately, with fetal serum levels approximately 10-50% of maternal levels. It is not as extensively transported as glyburide. |
| Breastfeeding | Glipizide is excreted into breast milk in low amounts. Although not expected to cause adverse effects in nursing infants, monitor for signs of hypoglycemia. Consider alternative agents with more safety data, such as glyburide or insulin. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Diapide is contraindicated in pregnancy due to known teratogenic effects. First trimester exposure is associated with increased risk of congenital malformations, particularly cardiovascular and neural tube defects. Second and third trimester exposure may cause fetal hyperinsulinemia, macrosomia, and neonatal hypoglycemia. |
| Fetal Monitoring | Monitor blood glucose levels in the mother. For fetal monitoring, consider ultrasound for fetal growth anomalies if exposed. Newborns should be monitored for hypoglycemia, jaundice, and electrolyte imbalances. |
| Fertility Effects | Diapide may impair fertility in females due to hormonal disturbances. In males, it may cause reversible spermatogenic suppression. Specific animal studies show reduced conception rates. |
■ FDA Black Box Warning
None.
| Serious Effects |
Type 1 diabetes mellitusDiabetic ketoacidosis (with or without coma)Known hypersensitivity to glipizide or sulfonylureasSevere hepatic or renal impairment
| Precautions | Monitor fluid and electrolyte balance to avoid water intoxication and hyponatremia., Use with caution in patients with coronary artery disease, hypertension, or renal impairment., May cause anaphylaxis or hypersensitivity reactions. |
| Food/Dietary | No significant food interactions. However, avoid excessive water intake and alcohol, which can affect ADH secretion. |
| Clinical Pearls | Diapid (desmopressin) is used for central diabetes insipidus and nocturnal enuresis. Monitor for hyponatremia, especially in elderly or patients with fluid/electrolyte imbalance. Avoid overhydration. Intranasal formulation may cause rhinitis or epistaxis. |
| Patient Advice | Use exactly as prescribed; do not exceed dose to avoid water intoxication. · Limit fluid intake to prevent hyponatremia (symptoms: headache, nausea, confusion). · For intranasal spray, gentle priming and alternating nostrils each dose. · Report signs of low sodium: severe headache, vomiting, muscle cramps, drowsiness. |
Loading safety data…